Study record managers: refer to the Data Element Definitions if submitting registration or results information. The primary objective of this study is to determine the response rate in patients with taxane-resistant metastatic breast cancer treated with capecitabine plus tipifarnib. To evaluate toxicity in patients with taxane-resistant metastatic breast cancer treated with capecitabine plus tipifarnib.
Taxanes have remained a cornerstone of breast cancer treatment over the past three decades, improving the lives of patients with both early- and late-stage disease. The purpose of this review is to summarize the current role of taxanes, including an albumin-bound formulation that enhances delivery of paclitaxel to tumors, in the management of metastatic breast cancer MBC. Since the introduction of Cremophor EL-paclitaxel to the clinic in the mids, a substantial amount of investigation has gone into subjects such as formulation, dose, schedule, and taxane resistance, allowing physicians greater flexibility in treating patients with MBC.
Identify trials that have demonstrated a survival benefit with a modern chemotherapeutic agent or regimen in MBC. Summarize recent findings of randomized trials showing survival benefits with targeted therapy—chemotherapy combinations in MBC. Metastatic breast cancer MBC remains essentially incurable, and goals of therapy include the palliation of symptoms, delay of disease progression, and prolongation of overall survival time without negatively impacting quality of life.
Technology appraisal guidance [TA] Published date: 23 February Evidence-based recommendations on bevacizumab Avastinwith a taxane, for treating metastatic breast cancer in adults. We reviewed the evidence in September
Metastatic breast cancer is breast cancer that has spread beyond the breast area to other places in the body, such as the bones, lungs, liver, or brain. Metastatic breast cancer is considered advanced-stage disease. Researchers wanted to know if an experimental chemotherapy medicine, called S-1, offered the same benefits as taxane chemotherapy medicines as the first chemotherapy treatment for metastatic, HER2-negative breast cancer.
Background: Capecitabine monotherapy is usually used for advanced breast cancer ABC resistant to anthracycline and taxane, but there are still many other options too. Our meta-analysis assessed whether capecitabine monotherapy was superior or noninferior to the other regimens in ABC pretreated with anthracycline and taxane. Materials and Methods: PubMed databases and abstracts from the proceedings of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium were searched for randomized controlled trials that compared capecitabine monotherapy with other regimens for ABC progression after anthracycline- and taxane-treatment.
Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer.
As with many other types of chemotherapy, taxanes are associated with side effects that can affect patients' quality of life. One of the major side effects of taxane therapy is taxane-induced peripheral neuropathy TIPN. The development of TIPN is accompanied by troublesome burning, tingling, and numbness; TIPN also can affect patient safety because of the decreased ability to perceive sensations e. Pain and fatigue are common side effects of taxane therapy.
In fact,breast cancer is the most common cancer among women, except for non-melanoma skin cancer, and women living in North America have the highest rate of breast cancer in the world. Inaboutnew cases of invasive breast cancer will be diagnosed among women in the US, and an estimated 1, cases of breast cancer will be diagnosed in men. Breast cancer is the second leading cause of cancer death in women,exceeded only by lung cancer.
By Caroline Helwick July 25, Advertisement. Seidman, MDand colleagues from several cancer centers. These patients are in need of more options that allow them to maintain their quality of life while on treatment. As the data suggested, tesetaxel offers the benefits of a taxane, but with oral administration, which may help address this unmet need.